Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAssist Therapeutics Co., Ltd. to develop circVec-enhanced AAV vectors engineered for in vivo cell therapy and low dose systemic gene therapy. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Oslo, Norway.
Frequently asked questions
What sector does Circio Holding ASA (CRNA) operate in?
Circio Holding ASA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Circio Holding ASA (CRNA) current stock price?
As of the latest data, Circio Holding ASA stock price is NOK 9.13, with a previous close of NOK 9.44. Circio Holding ASA lost -NOK 0.31 in the last trading session, representing a -3.28% loss.
What is Circio Holding ASA (CRNA) current market capitalization?
Circio Holding ASA market cap is approximately 2.51 billion.
What is Circio Holding ASA (CRNA) Earnings Per Share (EPS)?
The trailing EPS is -NOK 0.43.
Does Circio Holding ASA (CRNA) pay dividends?
No. Circio Holding ASA does not pay a dividend.
When is Circio Holding ASA (CRNA) next earnings report?
Circio Holding ASA is expected to release its next earnings report on June 30, 2026.
What is Circio Holding ASA (CRNA) beta (volatility) score?
Circio Holding ASA has a beta of -1.165, indicating lower volatility than the overall market.
